Jiang Jianjie, Au Melinda, Lu Kuanghui, Eshpeter Alana, Korbutt Gregory, Fisk Greg, Majumdar Anish S
Cell Therapy Research, Geron Corporation, Menlo Park, CA 94025, USA.
Stem Cells. 2007 Aug;25(8):1940-53. doi: 10.1634/stemcells.2006-0761. Epub 2007 May 17.
Recent success in pancreatic islet transplantation has energized the field to discover an alternative source of stem cells with differentiation potential to beta cells. Generation of glucose-responsive, insulin-producing beta cells from self-renewing, pluripotent human ESCs (hESCs) has immense potential for diabetes treatment. We report here the development of a novel serum-free protocol to generate insulin-producing islet-like clusters (ILCs) from hESCs grown under feeder-free conditions. In this 36-day protocol, hESCs were treated with sodium butyrate and activin A to generate definitive endoderm coexpressing CXCR4 and Sox17, and CXCR4 and Foxa2. The endoderm population was then converted into cellular aggregates and further differentiated to Pdx1-expressing pancreatic endoderm in the presence of epidermal growth factor, basic fibroblast growth factor, and noggin. Soon thereafter, expression of Ptf1a and Ngn3 was detected, indicative of further pancreatic differentiation. The aggregates were finally matured in the presence of insulin-like growth factor II and nicotinamide. The temporal pattern of pancreas-specific gene expression in the hESC-derived ILCs showed considerable similarity to in vivo pancreas development, and the final population contained representatives of the ductal, exocrine, and endocrine pancreas. The hESC-derived ILCs contained 2%-8% human C-peptide-positive cells, as well as glucagon- and somatostatin-positive cells. Insulin content as high as 70 ng of insulin/mug of DNA was measured in the ILCs, representing levels higher than that of human fetal islets. In addition, the hESC-derived ILCs contained numerous secretory granules, as determined by electron microscopy, and secreted human C-peptide in a glucose-dependent manner. Disclosure of potential conflicts of interest is found at the end of this article.
胰腺胰岛移植最近取得的成功激发了该领域探索具有分化为β细胞潜力的干细胞替代来源的热情。从自我更新的多能人类胚胎干细胞(hESCs)生成对葡萄糖有反应、能产生胰岛素的β细胞在糖尿病治疗方面具有巨大潜力。我们在此报告一种新型无血清方案的研发,该方案用于从无饲养层条件下培养的hESCs生成能产生胰岛素的胰岛样簇(ILCs)。在这个为期36天的方案中,hESCs用丁酸钠和激活素A处理以生成共表达CXCR4和Sox17以及CXCR4和Foxa2的确定内胚层。然后将内胚层群体转化为细胞聚集体,并在表皮生长因子、碱性成纤维细胞生长因子和头蛋白存在的情况下进一步分化为表达Pdx1的胰腺内胚层。此后不久,检测到Ptf1a和Ngn3的表达,表明胰腺进一步分化。聚集体最终在胰岛素样生长因子II和烟酰胺存在的情况下成熟。hESC来源的ILCs中胰腺特异性基因表达的时间模式与体内胰腺发育显示出相当大的相似性,最终群体包含导管、外分泌和内分泌胰腺的代表细胞。hESC来源的ILCs含有2% - 8%的人C肽阳性细胞,以及胰高血糖素和生长抑素阳性细胞。在ILCs中测得的胰岛素含量高达70 ng胰岛素/μg DNA,高于人类胎儿胰岛的水平。此外,通过电子显微镜确定,hESC来源的ILCs含有大量分泌颗粒,并以葡萄糖依赖的方式分泌人C肽。潜在利益冲突的披露见本文末尾。